Related Experiment Video
Updated: Jul 18, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Cyclooxygenase-2 polymorphisms in Parkinson's disease
Anna Håkansson1, Olle Bergman, Cecilia Chrapkowska
1Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden. anna.hakansson@pharm.gu.se
Summary
Genetic variants in the cyclooxygenase-2 (COX-2) gene may influence Parkinson's disease (PD) risk. A specific COX-2 gene variant (C8473T) showed a differing allele frequency in male PD patients compared to controls.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Cyclooxygenase-2 (COX-2) plays a role in Parkinson's disease (PD) neurodegeneration.
- NSAID use is linked to a reduced risk of developing PD.
- Genetic variations in COX-2 may affect PD susceptibility.
Purpose of the Study:
- To investigate the association between common single nucleotide polymorphisms (SNPs) in the COX-2 gene and Parkinson's disease risk.
- To analyze genotype distributions of four specific COX-2 SNPs in a Swedish population.
Main Methods:
- Genotyping of four common COX-2 gene SNPs (rs689466:A496G, rs20417:G926C, rs5277:G3050C, rs5275:C8473T).
- Comparison of genotype distributions between Parkinson's disease patients and control subjects in a Swedish cohort.
- Stratified analysis by sex.
Main Results:
- No significant differences were observed for SNPs rs689466, rs20417, and rs5277 between PD patients and controls.
- A statistically significant difference in allele frequency was found for the COX-2 C8473T SNP (rs5275) in male PD patients compared to male controls (P = 0.007).
- No significant association was found for the C8473T SNP in female PD patients.
Conclusions:
- The COX-2 C8473T gene variant may be associated with an increased risk of Parkinson's disease, particularly in men.
- Further research is warranted to elucidate the specific role of COX-2 genetic variations in Parkinson's disease pathogenesis.
- These findings highlight potential sex-specific genetic influences in Parkinson's disease.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...